[1] WHO. Weekly epidemiological update[EB/OL]. (2021-05-16) [2021-05-28]. https://covid19.who.int/table.
[2] Chan JF, Yuan S, Kok KH, et al.A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523.
[3] WHO. Draft landscape and tracker of COVID-19 candidate vaccines[EB/OL]. (2021-03-03) [2021-03-15].https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[4] 朱瑶,韦意娜,孙畅,等.新型冠状病毒肺炎疫苗研究进展[J].预防医学, 2021, 33(2): 143-148.
[5] 宋全伟,王华庆.不同技术路线研发新型冠状病毒疫苗的特性和研究进展[J].中华医学杂志, 2020, 100(38): 3030-3040.
[6] WHO. Number of vaccine approvals[EB/OL].(2021-01-10)[2021-05-10]. https://app.powerbi.com/view?r=eyJrIjoiNmE0YjZiNzUtZjk2OS00ZTg4LThlMzMtNTRhNzE0NzA4YmZlIiwidCI6Ijc3NDEwMTk1LTE0ZTEtNGZiOC05MDRiLWFiMTg5MjAyMzY2NyIsImMiOjh9&pageName=ReportSectiona329b3eafd86059a947b.
[7] 卫生部. 全国疑似预防接种异常反应监测方案[J].中国疫苗和免疫, 2011, 17(1): 72-81.
[8] 中国疾病预防控制中心.新冠病毒疫苗接种问答[EB/OL].(2021-01-07) [2021-02-28]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_12208/202101/t20210107_223665.html.
[9] Turner PJ, Ansotegui IJ, Campbell DE, et al.COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee[J]. World Allergy Organ J, 2021, 14(2): 100517.
[11] Bournazos S, Gupta A, Ravetch JV.The role of IgG Fc receptors in antibody-dependent enhancement[J]. Nat Rev Immunol, 2020, 20(10): 633-643.
[12] Kuzmina NA, Younan P, Gilchuk P, et al. Antibody-dependent enhancement of ebola virus infection by human antibodies isolated from survivors [J]. Cell Reports, 2018, 24(7): 1802-15.e5.
[13] Deng SQ, Yang X, Wei Y, et al.A review on dengue vaccine development[J]. Vaccines (Basel), 2020, 8(1): 63.
[14] Lee WS, Wheatley AK, Kent SJ, et al.Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies[J]. Nat Microbiol, 2020, 5(10): 1185-1191.
[15] 宁桂军,吴丹,李军宏,等.应用中断时间序列分析评价流行性乙型脑炎减毒活疫苗大规模预防接种的有效性[J].中国疫苗和免疫, 2015, 21(4): 361-364.
[16] Moderna. Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE Study[EB/OL].(2020-12-16)[2021-03-04]. https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
[17] Polack FP, Thomas SJ, Kitchin N, et al.Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine[J]. N Engl J Med, 2020, 383(27): 2603-2615.
[18] Voysey M, Costa Clemens SA, Madhi SA, et al.Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials[J]. Lancet, 2021, 397(10277):881-891.
[19] 环球网.中国新冠病毒疫苗上市,临床实验保护性数据结果达到预定目标[EB/OL].(2020-12-31)[2021-05-11].https://health.huanqiu.com/article/41K8WTDwnV6.
[20] WHO. WHO target product profiles for COVID-19 vaccines. (2020-04-29)[2021-03-03]. https://www.who.int/who-documents-detail/who-target-product-profiles-for-covid-19-vaccines.
[21] Muik A, Wallisch AK, Sanger B, et al.Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera[J]. Science, 2021, 371(6534):1152-1153.
[22] Wang Z, Schmidt F, Weisblum Y, et al.mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants[J]. Nature, 2021, 592(7855):616-622.
[23] Meristem Research. Bracing for a different future[EB/OL]. (2021-01-01)[2021-05-11]. https://www.proshareng.com/report/Nigerian20Economy/Meristem-2021-Outlook--Bracing-for-A-Different-Future/14319.
[24] Burak Kazaz, Scott Webster, Prashant Yadav. Incentivizing COVID-19 vaccine developers to expand manufacturing capacity[EB/OL].(2021-03-26)[20121-05-11]. https://www.cgdev.org/publication/incentivizing-covid-19-vaccine-developers-expand-manufacturing-capacity.
[25] 邓子如,严非,王伟,等.国际组织关于疫苗冷链配送的实践启示[J].上海预防医学,2021,33(2):141-145.
[26] 于孟轲,吴疆,吕敏,等.影响疫苗接种的社会因素综述[J].中国疫苗和免疫,2019,25(3):340-344. |
